Mirum price target raised at Baird after preliminary results

As previously reported, Baird raised the firm’s price target on Mirum Pharmaceuticals (MIRM) to $95 from $88 and keeps an Outperform rating on the shares after Mirum’s preliminary Q4 and FY25 sales came in ahead of expectations, including the upper end of their guidance. Management apparently sees durability in the performance with guidance for continued strong growth in 2026, adds the analyst, who is raising the firm’s price target citing the commercial strength.